Arrowhead Pharmaceuticals, Inc. (ARWR) vs Kymera Therapeutics, Inc. (KYMR)

Arrowhead Pharmaceuticals, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. and Kymera Therapeutics, Inc. are of similar size ($9.7B and $9.3B). Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 16.1%. Arrowhead Pharmaceuticals, Inc. has the higher net margin (−47.8% vs −285.3%) and the higher return on invested capital (0.00% vs −26.7%). Across the 17 metrics below, Arrowhead Pharmaceuticals, Inc. leads on 11 and Kymera Therapeutics, Inc. on 6.

Valuation

Metric ARWR KYMR Biotechnology median
P/E n/m n/m 7.88
P/S 14.12 105.17 11.47
P/B 20.28 7.32 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.02 98.60 10.73
Earnings yield (3.41%) (2.88%) (28.84%)
Free cash flow yield (0.79%) (2.15%) (23.03%)

Profitability

Metric ARWR KYMR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (33.82%) (333.50%) 0.00%
Net margin (47.79%) (285.33%) 0.00%
Free cash flow margin (11.22%) (226.62%) 0.00%
Return on equity (64.91%) (24.15%) (57.72%)
Return on assets (18.32%) (21.58%) (49.22%)
Return on invested capital 0.00% (26.72%) 0.00%

Growth

Metric ARWR KYMR Biotechnology median
Revenue growth (TTM) 16.13% 134.84% 5.64%
EPS growth (last fiscal year) 99.80% (23.83%) —
Revenue growth, 5-year CAGR 56.63% 2.87% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARWR KYMR Biotechnology median
Debt to equity 1.85 0.00 0.00
Current ratio 5.90 10.34 4.73
Net debt to EBITDA (5.70) 2.42 0.96

Dividend

Metric ARWR KYMR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARWR KYMR Biotechnology median
Market cap 9.33b 9.69b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack